RE:RE:RE:RE:RE:RE:Sales —-Thanks JFM. And this explanation would have been so very much better and logical than what was said.. it also puts the positive spin in the answer. It makes the company look incompitent when there is such a weak answer. When you have no answers other than some mumbling about the drug being on the market for a long time. Probably just me and my interpretation of the response but it really struck me the wrong way when I was listening. I thought really that is the answer??
jfm1330 wrote: The real answer was that Egrifta F1 is just an awful drug for the patient to take. Just awful. Injecting yourself 2 ml subcutaneous daily is very hard to do on the long run. You really need to be highly motivated. As I said many times, F4 should help a lot. So much easier.
stockman75 wrote: Yes the silence to that question was astounding. Really you can't at least come up with some type of explanation? Like you say coupled with the weak performance of trogarzo. The answer: yes we are focusing on trogarzo which isn't doing much of anything either. Great! thanks for a very weak explanation and weak performance on both fronts.
The energy of the call sounded pathetic to me. "We are very excited about our future" said in a dull boring monotone voice. Really gets me pumped up...